Peptides›GH secretagogue›GHRP-7

GHRP-7

/ Synthetic hexapeptide growth-hormone-releasing peptide (GHS-R1a agonist class)

SPECULATIVEN = 0 · TESTING PENDING

ALIAS · Growth Hormone Releasing Peptide-7

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Synthetic hexapeptide growth-hormone-releasing peptide (GHS-R1a agonist class)CATEGORY · GH secretagogue

Tier 4. GHRP-7 is part of the synthetic GHRP class developed in the 1980s-1990s but received almost no clinical development relative to GHRP-2, GHRP-6, or hexarelin. No identifiable pivotal trial; preclinical pharmacology only.

§ B · Mechanism of action

GHRP-7 is a synthetic GHS-R1a agonist of the same broad pharmacological class as GHRP-2, GHRP-6, and hexarelin — drives pituitary GH release through ghrelin receptor agonism. Specific potency, selectivity, and PK relative to its better-studied class members are not well-characterised in published literature.

§ C · Human clinical evidence

None substantive. The molecule is largely orphaned in the published record relative to its sibling GHRPs.

§ F · Safety signal

No formal human safety database. Class concerns from sustained GHS-R1a agonism apply.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Vendor sales of 'GHRP-7' often present it as a refinement over GHRP-2 / GHRP-6 with better profile. There is no published evidence supporting that claim. Buyers cannot distinguish vendor-labelled GHRP-7 from misidentified material without independent identity testing.